ArticleApplied network science2025
The association of prescriber prominence in a shared-patient physician network with their patients receipt of and transitions between risky drug combinations.
Article in Applied network science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We are generally interested in the association between a prescribing physician's position in a physician shared-patient network and their patients' receipt of risky drug combinations. An informal physician network (not restricted to a hospital or a health system) of physicians based in Ohio was constructed based on overlapping care of patients between physicians reflected in face-to-face visits in Fee-for-service Medicare claims for Ohio-residing beneficiaries. Separately, Medicare prescription drug events for beneficiaries receiving opioids, benzodiazepines, or non-benzodiazepine sedative hypnotics (sedative hypnotics) prescribed by these physicians in 2014 were used to map patients' drug status with respect to these three classes. We assigned patient prescription receipt to time-varying drug states and linked each drug state transition to a "responsible" prescribing physician. Outcomes of interest include transitions across drug states, particularly those resulting in combinations of increased risk (e.g., a benzodiazepine or sedative hypnotic with an opioid), and patients' time to discontinuation of overlapping prescriptions of an opioid, benzodiazepine, and a sedative hypnotic while the key predictors of these transitions reflected characteristics of a prescriber's physician network position and physician speciality. We found that among beneficiaries receiving none of the three risky drug groups, patients seeing physicians with higher closeness centrality (shorter average path lengths to other physicians through the network) were less likely to transition to two or three risky drugs; and they were more likely to discontinue overlapping prescriptions of an opioid, benzodiazepine, and sedative hypnotic. Compared to PCPs, psychiatrists appeared more likely to prescribe risky drug combinations, and their patients were less likely to discontinue overlapping three-drug prescriptions. This work demonstrates that characterizing physicians' prescribing behavior in relation to their position in shared-patient networks may reveal strategies for optimizing network-based interventions to improve prescribing quality. Supplementary Information: The online version contains supplementary material available at 10.1007/s41109-025-00721-y.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.